Eurofins Selcia

Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities.  www.selcia.com 

 

  • 14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate)  
  • GMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance  
  • Stable Labelling  (13C, 2H, 15N) Internal Standards, Metabolites and Impurities  
  • GLP Analysis Certification and Problem Solving including GLP NMR 

 

Radiolabelling to support Life Sciences: • Metabolism • Distribution • Mass Balance • Micro-dosing • Environmental fate • Dermal Penetration 

Company Type
Keywords
Twitter Account
@SelciaLtd
News Page URL
Click here

Sygnature Discovery

Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services CRO. Founded in 2004 and private equity-backed since 2017, we operate a fully-enabled research facility in Nottingham, UK, housing nearly 400 staff (80% of our scientists have PhDs). Our experienced R&D scientists possess all the professional skills and know-how required to undertake the most demanding of drug discovery and/or pre-clinical development projects and drive them from target validation, through hit identification, hit-to-lead and lead optimization to development candidate. Sygnature collaborates with its partners via risk share and FTE-based collaborations.